Multiple Sclerosis Discovery Forum

Inspiring Connections

Most Viewed

Novel Immune Regulator Shows Promise as MS Therapy in Clinical Trials
Childhood obesity and risk of pediatric multiple sclerosis and clinically isolated syndrome.
Efficacy and safety of Privigen(®) in patients with chronic inflammatory demyelinating polyneuropathy: results of a prospective, single-arm, open-label Phase III study (the PRIMA study).
Asymptomatic lung disease caused by Mycobacterium kansasii as an opportunistic infection in a patient treated with natalizumab for relapsing-remitting multiple sclerosis.
High-field imaging of neurodegenerative diseases.
Cyclophosphamide
Development of the Brief Inventory of Perceived Stress.
Cluster-tic syndrome as the initial manifestation of multiple sclerosis.
Alemtuzumab treatment of multiple sclerosis: long-term safety and efficacy.
Reduction of inflammation and preservation of neurological function by anti-CD52 therapy in murine experimental autoimmune encephalomyelitis.
Epstein-Barr virus in the multiple sclerosis brain: a controversial issue--report on a focused workshop held in the Centre for Brain Research of the Medical University of Vienna, Austria.
A systematic review of research undertaken in vocational rehabilitation for people with multiple sclerosis.
Fingolimod and CSF neurofilament light chain levels in relapsing-remitting multiple sclerosis.
Predictors of quality of life among multiple sclerosis patients: a comprehensive analysis.
Biogen Idec announces positive top-line results from Phase 3 study of peginterferon beta-1a in multiple sclerosis
Interferon beta-1a in primary progressive MS: an exploratory, randomized, controlled trial.
Rehabilitation interventions in multiple sclerosis: an overview.
Stress signaling etches heritable marks on chromatin.
Lipocalin 2 is present in the EAE brain and is modulated by natalizumab.
Long-Term Safety and Efficacy Study of BIIB017 (PEGylated Interferon Beta-1a) (ATTAIN)
Arzerra receives approval in Japan
RGC-32 as a potential biomarker of relapse and response to treatment with glatiramer acetate in multiple sclerosis.
The therapeutic potential of mesenchymal stem cell transplantation as a treatment for multiple sclerosis: consensus report of the International MSCT Study Group.
Overcoming barriers in progressive multiple sclerosis research.
First reported case of diabetes mellitus type 1 as a possible secondary autoimmune disease following alemtuzumab treatment in MS.

Pages